Скачать или смотреть Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia

Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia (Video Interview)

Interview conducted on July 11, 2025, by Dr Neil Love. Click on the CE Information link above for credits, learning objectives and faculty information. Featuring an interview with Dr Jorge Cortes. Published July 2025.

Topics:
• Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00)
• Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38)
• Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32)
• Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04)
• Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31)
• Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07)
• Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53)

The complete program, slides, CME information, and selected publications:
https://www.researchtopractice.com/On...